1. Home
  2. RIV vs TRDA Comparison

RIV vs TRDA Comparison

Compare RIV & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIV
  • TRDA
  • Stock Information
  • Founded
  • RIV 2015
  • TRDA 2016
  • Country
  • RIV United States
  • TRDA United States
  • Employees
  • RIV N/A
  • TRDA N/A
  • Industry
  • RIV Finance Companies
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • RIV Finance
  • TRDA Health Care
  • Exchange
  • RIV Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • RIV 258.5M
  • TRDA 301.0M
  • IPO Year
  • RIV N/A
  • TRDA 2021
  • Fundamental
  • Price
  • RIV $12.02
  • TRDA $7.12
  • Analyst Decision
  • RIV
  • TRDA Strong Buy
  • Analyst Count
  • RIV 0
  • TRDA 3
  • Target Price
  • RIV N/A
  • TRDA $25.67
  • AVG Volume (30 Days)
  • RIV 87.6K
  • TRDA 126.5K
  • Earning Date
  • RIV 01-01-0001
  • TRDA 08-12-2025
  • Dividend Yield
  • RIV 12.85%
  • TRDA N/A
  • EPS Growth
  • RIV N/A
  • TRDA N/A
  • EPS
  • RIV N/A
  • TRDA 0.61
  • Revenue
  • RIV N/A
  • TRDA $172,220,000.00
  • Revenue This Year
  • RIV N/A
  • TRDA N/A
  • Revenue Next Year
  • RIV N/A
  • TRDA N/A
  • P/E Ratio
  • RIV N/A
  • TRDA $11.70
  • Revenue Growth
  • RIV N/A
  • TRDA 5.74
  • 52 Week Low
  • RIV $9.63
  • TRDA $6.94
  • 52 Week High
  • RIV $12.43
  • TRDA $21.79
  • Technical
  • Relative Strength Index (RSI)
  • RIV 52.71
  • TRDA 36.18
  • Support Level
  • RIV $11.94
  • TRDA $6.94
  • Resistance Level
  • RIV $12.25
  • TRDA $8.49
  • Average True Range (ATR)
  • RIV 0.10
  • TRDA 0.42
  • MACD
  • RIV -0.03
  • TRDA -0.07
  • Stochastic Oscillator
  • RIV 25.81
  • TRDA 10.91

About RIV RiverNorth Opportunities Fund Inc.

Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: